ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
8 hedge funds and large institutions have $4.2M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
96,980% more call options, than puts
Call options by funds: $4.85M | Put options by funds: $5K
250% more capital invested
Capital invested by funds: $1.2M → $4.2M (+$3M)
100% more funds holding
Funds holding: 4 → 8 (+4)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$1.16M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$966K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$410K |
| 4 |
Morgan Stanley
New York
|
+$347K |
| 5 |
Goldman Sachs
New York
|
+$324K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$532K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
-$396K |
| 3 |
Jane Street
New York
|
-$155K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $1.14M | +$1.16M | +15,706 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $944K | +$966K | +13,034 | New |
|
|
3
Jane Street
New York
| $769K | -$155K | -2,091 | -16% |
|
|
4
Simplex Trading
Chicago,
Illinois
| $400K | +$410K | +5,531 | New |
|
|
5
Morgan Stanley
New York
| $389K | +$347K | +4,680 | +679% |
|
|
6
Goldman Sachs
New York
| $316K | +$324K | +4,367 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $177K | -$532K | -7,179 | -75% |
|
|
CG
8
Cutler Group
San Francisco,
California
| $68K | -$396K | -5,350 | -85% |
|
ZBIO Hedge Fund Activity: Q1 2016 in Review
8 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q1 2016, worth a combined $4.2M — up 250% from $1.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ZBIO positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $1.16M. The largest seller was Tower Research Capital (TRC), cutting an estimated $532K.
- 8 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q1 2016, up from 4 in Q4 2015.
- Funds reported $4.2M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q1 2016, up 250% quarter-over-quarter.
- 4 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q1 2016 and 0 closed out, a net change of +4 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q1 2016 was Virtu Financial, an estimated $1.16M added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q1 2016 was Tower Research Capital (TRC), an estimated $532K sold.
Based on aggregated 13F filings for Q1 2016.